Halozyme Therapeutics Inc (HALO)
46.93
-0.39
(-0.82%)
USD |
NASDAQ |
Dec 20, 16:00
46.95
+0.02
(+0.04%)
After-Hours: 20:00
Halozyme Therapeutics Revenue (Quarterly): 290.08M for Sept. 30, 2024
Revenue (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Revenue (Quarterly) Benchmarks
| Lexicon Pharmaceuticals Inc | 1.75M |
| Novavax Inc | 84.51M |
| Kura Oncology Inc | -- |
| TransMedics Group Inc | 108.76M |
| Pulmonx Corp | 20.39M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | 137.01M |
| Total Expenses (Quarterly) | 126.89M |
| EPS Diluted (Quarterly) | 1.05 |
| Enterprise Value | 6.809B |
| Gross Profit Margin (Quarterly) | 82.96% |
| Profit Margin (Quarterly) | 47.23% |
| Earnings Yield | 6.44% |
| Operating Earnings Yield | 7.83% |
| Normalized Earnings Yield | 6.142 |